MedTrace Logo

Postop Pain Control in Hip Fracture Surgery: Fascia Iliaca Compartment Block Versus Fracture Block

NCT04335461 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2023-07-13

No results posted yet for this study

Summary

The investigators propose to investigate the effect of intraoperative FICB and intrafragmentary fracture blockade on postoperative pain and opiate consumption using a randomized controlled trial study design. There will be three treatment groups: (1) fascia iliaca compartment blockade administered after surgical fixation using the loss of resistance technique with 30cc 0.25% marcaine (2) intrafragmentary fracture block using fluoroscopy guidance after surgical fixation with 30cc 0.25% marcaine and (3) placebo group, with no intervention.

Conditions

  • Hip Fractures
  • Analgesia
  • Opioid Use
  • Pain, Postoperative

Interventions

PROCEDURE

Cephalomedullary nailing of extracapsular hip fracture

All patients will undergo cephalomedullary nailing of their extracapsular hip fractures. Both short and long nails will be used based on fracture morphology.

DEVICE

cephalomedullary nail

Implants to be used will be variable, but include Stryker Gamma, Synthes Trochanteric Fixation Nail, Smith and Nephew Intertan.

DRUG

Regional Anesthetics

Marcaine 0.25% will be administered for the two experimental arms, as described in above protocol.

Sponsors & Collaborators

  • Jacobi Medical Center

    collaborator OTHER

  • Montefiore Medical Center

    lead OTHER

Principal Investigators

  • Milan Sen · Jacobi Medical Center; Albert Einstein College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-05
Primary Completion
2023-03-17
Completion
2023-03-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04335461 on ClinicalTrials.gov